Clinical Trial: Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07465926) titled 'Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3' on March 08.

Brief Summary: This observational target-trial emulation study uses routinely collected electronic health record data from the TriNetX US Collaborative Network to compare early add-on treatment strategies in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3. The study evaluates outcomes among people who start a GLP-1 receptor agonist or an SGLT2 inhibitor and then, within 90 days, either add the alternate therapy, add a DPP-4 inhibitor or sulfonylurea, or do ...